1.3 Assessment of Risk

Assessment of Risk

Quick Answer: An Assessment of Risk (AoR) is a documented, facility-level process USP <800> permits for certain lower-risk hazardous drug (HD) activities — primarily final dosage forms that require only counting, weighing, or repackaging, not compounding or manipulation — to determine whether alternative containment strategies and work practices can be used instead of the full engineering-control requirements of the chapter. An AoR must be documented, must use at minimum single chemotherapy gloves, and cannot be used to bypass primary engineering controls for compounding antineoplastic drugs or NIOSH Table 1 drugs.

The Assessment of Risk is USP <800>'s built-in escape valve — a way to avoid over-engineering a low-risk task like counting tablets into a vial, while still requiring facilities to justify and document that decision. It is also one of the most frequently misapplied provisions in real practice, which is exactly why it shows up on the exam.

What an AoR Is — and Is Not

An AoR is not a blanket exemption from <800>. It is a structured, documented risk evaluation a facility performs for a specific, eligible activity to decide whether reduced containment is appropriate. The facility must consider factors such as:

• The type of HD and its NIOSH table classification
• The dosage form and whether it requires manipulation
• The risk of exposure during the specific task
• Packaging and any manufacturer-specific handling information

If the facility completes this evaluation and documents its rationale, it may implement alternative containment strategies or PPE for that specific task — but the documentation itself is a requirement, not optional paperwork.

Which Activities Are Eligible

The clearest, most heavily tested eligibility line is manipulation:

Exam trap: an AoR can reduce containment expectations for counting/repackaging final dosage forms, but it can never substitute for a certified primary engineering control (a biological safety cabinet or compounding aseptic containment isolator) when an antineoplastic drug is actually being compounded or manipulated. If a scenario describes compounding, manipulation, or an antineoplastic preparation, the AoR pathway is not available to skip the required engineering controls.

The Minimum Floor: Single Chemo Gloves

Even when an AoR justifies reduced containment for an eligible activity, USP <800> sets a floor: at minimum, single chemotherapy gloves meeting the required testing standard must still be worn. An AoR can reduce some requirements (for example, whether a dedicated ventilated cabinet is required for counting tablets), but it cannot eliminate glove protection entirely. A facility that concludes "no PPE needed" for HD tablet counting, based on an AoR, has misapplied the tool.

Table 1 vs. Table 2 and AoR Eligibility

Because Table 1 drugs (MSHI and/or NTP/IARC carcinogen classification) carry the strongest hazard evidence, they are poor — often ineligible — candidates for AoR-based containment reduction, especially for any activity beyond simple counting/repackaging of an unaltered final dosage form. Table 2 drugs, which meet a NIOSH hazard criterion without carcinogen classification, are more commonly the drugs a facility can successfully justify handling with an AoR-based alternative approach. This is one more reason the Table 1/Table 2 distinction from the NIOSH list (covered in the previous section) is foundational — you cannot correctly reason through an AoR question without first knowing which table a drug falls into.

Exam Scenario

A retail pharmacy technician routinely counts an oral oncology tablet — a final dosage form, not compounded — from a stock bottle into a vial for dispensing. The pharmacy has completed and documented an Assessment of Risk for this specific task, concluding that a dedicated ventilated device is not required for simple counting of this intact tablet, but requiring single chemotherapy gloves and a dedicated counting tray at minimum. A new technician assumes the AoR means no special handling is needed at all and counts the tablets bare-handed with the store's shared counting tray. This violates the documented AoR itself — the AoR reduced some requirements but preserved others (gloves, dedicated equipment), and it never eliminated PPE.

Key Takeaways

• An AoR is a documented, task-specific risk evaluation — not a blanket exemption from USP <800>.
• AoR eligibility is generally limited to final dosage forms needing only counting, weighing, or repackaging — not compounding or manipulation.
• At minimum, single chemotherapy gloves are still required even when an AoR justifies reduced containment elsewhere.
• Antineoplastic drugs requiring manipulation and NIOSH Table 1 drugs generally cannot use an AoR to bypass required primary engineering controls for compounding.